Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,936.90	12.50	-0.14%
CAC 40	8,141.92	15.90	-0.19%
DAX 40	24,083.53	45.45	-0.19%
Dow JONES (US)	49,167.79	62.92	-0.13%
FTSE 100	10,321.09	57.99	-0.56%
HKSE	25,703.77	221.88	-0.86%
NASDAQ	24,887.10	50.50	0.20%
Nikkei 225	59,937.88	599.48	-0.99%
NZX 50 Index	12,764.40	110.54	-0.86%
S&P 500	7,173.91	8.83	0.12%
S&P/ASX 200	8,712.90	8.30	-0.10%
SSE Composite Index	4,078.78	7.56	-0.19%